secwatch.observer — SEC 8-K summary
======================================

Issuer:     CorMedix Inc. (CRMD)
CIK:        0001410098
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0001213900-23-086937
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CorMedix Q3 net loss $9.7M; FDA inspections complete, launch targeted by Q1 2024
--------------------------------------------------------------------------------

- Net loss $9.7M ($0.17/sh) vs $6.9M ($0.17/sh) in Q3 2022; operating expenses up 50% to $10.5M.
- Cash and short-term investments $86.6M as of Sept 30, 2023; sufficient for at least 12 months.
- FDA completed preapproval inspections at primary CMO and key suppliers; no known deficiencies.
- USPTO issued patent for DefenCath composition-of-matter (expiry April 2042).
- Commercial launch targeted before end of Q1 2024 if FDA approval received.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1410098/000121390023086937/0001213900-23-086937-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1410098/000121390023086937/ea188304-8k_cormedix.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-086937

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer